Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Criteria for the evaluating treatment on primary bone sarcoma]

H Fukuma1, I Sugiura, K Tomita

  • 1Department Orthopaedic Surgery, National Cancer Center Hospital, Tokyo, Japan.

Nihon Seikeigeka Gakkai Zasshi
|October 1, 1994
PubMed
Summary

The Japanese Orthopaedic Association (JOA) established criteria to evaluate primary bone sarcoma treatment response, classifying outcomes as complete response (CR), partial response (PR), no change (NC), or progressive disease (PD). These criteria assess radiographical, histopathological, and clinical factors, with preoperative chemotherapy response predicting survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world outcomes of treatment strategy between first-line osimertinib, first/second-generation EGFR-TKIs followed by osimertinib and without osimertinib in advanced EGFR-mutant NSCLC.

ESMO real world data and digital oncology·2026
Same author

High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.

Leukemia·2017
Same author

t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs.

Blood cancer journal·2015
Same author

[Repair of paravalvular leak after a third mitral valve replacement].

Kyobu geka. The Japanese journal of thoracic surgery·2007
Same author

Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan.

Leukemia·2007
Same author

Ex-vivo study of high-magnification chromoendoscopy in the gastrointestinal tract to determine the optimal staining conditions for endocytoscopy.

Endoscopy·2006

Area of Science:

  • Orthopedics
  • Oncology
  • Medical Imaging

Background:

  • Primary bone sarcoma treatment evaluation requires standardized criteria.
  • The Japanese Orthopaedic Association (JOA) developed specific criteria for assessing treatment response in bone sarcomas.

Purpose of the Study:

  • To present the established criteria for evaluating treatment response in primary bone sarcoma.
  • To outline the classification system for treatment outcomes: complete response (CR), partial response (PR), no change (NC), and progressive disease (PD).

Main Methods:

  • Radiographical assessment includes evaluating intramedullary lesions, bone trabeculae, and extraosseous tumor extent.
  • Histopathological evaluation focuses on viable tumor cells and treatment-induced necrosis percentages.
  • Clinical assessment considers symptoms (pain, local heat) and tumor size, alongside serum alkaline phosphatase levels.

Related Experiment Videos

Main Results:

  • Criteria define CR, PR, NC, and PD based on specific radiographical, histopathological, and clinical findings.
  • A minimum 4-week duration is required for CR, PR, or NC classifications.
  • The extent of response to preoperative chemotherapy is a significant predictor of patient survival.

Conclusions:

  • The JOA criteria provide a standardized framework for evaluating primary bone sarcoma treatment efficacy.
  • Accurate assessment of treatment response is crucial for patient management and predicting outcomes.
  • Preoperative chemotherapy response is a key factor influencing survival in bone sarcoma patients.